VAX 2012Q

Drug Profile

VAX 2012Q

Alternative Names: VAX2012Q

Latest Information Update: 16 Jul 2015

Price : $50

At a glance

  • Originator VaxInnate
  • Class DNA vaccines; Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 25 Jun 2015 VaxInnate completes enrolment in its phase II trial for Influenza virus infections (Prevention) in USA (NCT02434276)
  • 01 May 2015 Phase-II clinical trials in Influenza virus infections (Prevention) in USA (IM) (NCT02434276)
  • 07 Apr 2015 VaxInnate plans a phase II trial in Healthy volunteers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top